460 related articles for article (PubMed ID: 33333862)
1. Current Status on Therapeutic Molecules Targeting Siglec Receptors.
Lenza MP; Atxabal U; Oyenarte I; Jiménez-Barbero J; Ereño-Orbea J
Cells; 2020 Dec; 9(12):. PubMed ID: 33333862
[TBL] [Abstract][Full Text] [Related]
2. Advances in understanding and exploiting Siglec-glycan interactions.
Jame-Chenarboo Z; Gray TE; Macauley MS
Curr Opin Chem Biol; 2024 Jun; 80():102454. PubMed ID: 38631213
[TBL] [Abstract][Full Text] [Related]
3. Sensing the neuronal glycocalyx by glial sialic acid binding immunoglobulin-like lectins.
Linnartz-Gerlach B; Mathews M; Neumann H
Neuroscience; 2014 Sep; 275():113-24. PubMed ID: 24924144
[TBL] [Abstract][Full Text] [Related]
4. Tools to study and target the Siglec-sialic acid axis in cancer.
Läubli H; Kawanishi K; George Vazhappilly C; Matar R; Merheb M; Sarwar Siddiqui S
FEBS J; 2021 Nov; 288(21):6206-6225. PubMed ID: 33251699
[TBL] [Abstract][Full Text] [Related]
5. Preparation of Recombinant Siglecs and Identification of Their Ligands.
Chang LY; Low PY; Sridharan D; Gerlovin K; Angata T
Methods Mol Biol; 2020; 2132():85-98. PubMed ID: 32306317
[TBL] [Abstract][Full Text] [Related]
6. Siglecs as targets for therapy in immune-cell-mediated disease.
O'Reilly MK; Paulson JC
Trends Pharmacol Sci; 2009 May; 30(5):240-8. PubMed ID: 19359050
[TBL] [Abstract][Full Text] [Related]
7. A versatile soluble siglec scaffold for sensitive and quantitative detection of glycan ligands.
Rodrigues E; Jung J; Park H; Loo C; Soukhtehzari S; Kitova EN; Mozaneh F; Daskhan G; Schmidt EN; Aghanya V; Sarkar S; Streith L; St Laurent CD; Nguyen L; Julien JP; West LJ; Williams KC; Klassen JS; Macauley MS
Nat Commun; 2020 Oct; 11(1):5091. PubMed ID: 33037195
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.
Angata T; Nycholat CM; Macauley MS
Trends Pharmacol Sci; 2015 Oct; 36(10):645-660. PubMed ID: 26435210
[TBL] [Abstract][Full Text] [Related]
9. Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments.
Gianchecchi E; Arena A; Fierabracci A
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071314
[TBL] [Abstract][Full Text] [Related]
10. Discovery and expression of 3 siglecs-like in Oreochromis niloticus neutrophil, and their interaction with group B streptococcal sialylated capsular polysaccharides.
Dong J; Wei Y; Ye X; Sun C; Tian Y; Lu M; Du J; Chen Z
Mol Immunol; 2016 May; 73():158-69. PubMed ID: 26847490
[TBL] [Abstract][Full Text] [Related]
11. Siglec Signaling in the Tumor Microenvironment.
van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
Front Immunol; 2021; 12():790317. PubMed ID: 34966391
[TBL] [Abstract][Full Text] [Related]
12. Impact of Siglecs on autoimmune diseases.
Brzezicka KA; Paulson JC
Mol Aspects Med; 2023 Apr; 90():101140. PubMed ID: 36055802
[TBL] [Abstract][Full Text] [Related]
13. Probing the binding specificities of human Siglecs by cell-based glycan arrays.
Büll C; Nason R; Sun L; Van Coillie J; Madriz Sørensen D; Moons SJ; Yang Z; Arbitman S; Fernandes SM; Furukawa S; McBride R; Nycholat CM; Adema GJ; Paulson JC; Schnaar RL; Boltje TJ; Clausen H; Narimatsu Y
Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33893239
[TBL] [Abstract][Full Text] [Related]
14. Siglec Ligands.
Gonzalez-Gil A; Schnaar RL
Cells; 2021 May; 10(5):. PubMed ID: 34065256
[TBL] [Abstract][Full Text] [Related]
15. Targeting glycosylated antigens on cancer cells using siglec-7/9-based CAR T-cells.
Meril S; Harush O; Reboh Y; Matikhina T; Barliya T; Cohen CJ
Mol Carcinog; 2020 Jul; 59(7):713-723. PubMed ID: 32391973
[TBL] [Abstract][Full Text] [Related]
16. Targeting sialylation to treat central nervous system diseases.
Lünemann JD; von Gunten S; Neumann H
Trends Pharmacol Sci; 2021 Dec; 42(12):998-1008. PubMed ID: 34607695
[TBL] [Abstract][Full Text] [Related]
17. Siglec-8 and Siglec-9 binding specificities and endogenous airway ligand distributions and properties.
Yu H; Gonzalez-Gil A; Wei Y; Fernandes SM; Porell RN; Vajn K; Paulson JC; Nycholat CM; Schnaar RL
Glycobiology; 2017 Jul; 27(7):657-668. PubMed ID: 28369504
[TBL] [Abstract][Full Text] [Related]
18. Siglec and anti-Siglec therapies.
Murugesan G; Weigle B; Crocker PR
Curr Opin Chem Biol; 2021 Jun; 62():34-42. PubMed ID: 33607404
[TBL] [Abstract][Full Text] [Related]
19. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
Bärenwaldt A; Läubli H
Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
[No Abstract] [Full Text] [Related]
20. Siglecs: A journey through the evolution of sialic acid-binding immunoglobulin-type lectins.
Bornhöfft KF; Goldammer T; Rebl A; Galuska SP
Dev Comp Immunol; 2018 Sep; 86():219-231. PubMed ID: 29751010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
